Opinion|Videos|May 17, 2024
Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer
Author(s)Stephanie L. Graff, MD
Stephanie Graff, MD, concludes the discussion with thoughts on endocrine therapies in development for patients with ER+/HER2- metastatic breast cancer.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
2
As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning
3
ACO-SWITCH to Evaluate Tafamidis-to-Acoramidis Switch in ATTR-CM
4
FAQ: Prior Authorization Reform—Will Changes Go Far Enough by 2027?
5